Solid Tumor Immunotherapy Clinical Trial Strive-02
$100,000 in new funds ($50,000 donation, plus $50,000 MacDonald match) would cover research-related costs for the first 10 patients enrolled in this innovative treatment.
Community support is moving ahead new T-cell clinical trials in our pipeline that will bring hope to children fighting many kinds of cancer. You can help us develop these studies more quickly. Donors that wish to, may direct their support to a specific T-cell trial being developed at the Ben Towne Center for Childhood Cancer Research. The Solid Tumor Immunotherapy Clinical Trials fund is the top priority for Dr. Julie Park and Dr. Navin Pinto, providing resources to develop the STRIvE-02 phase I clinical trial for children with relapsed or refractory solid tumors outside of the brain. The chimeric antigen receptor (CAR) T cells developed for the STRIvE-02 trial will target the B7-H3 molecule which is present on the surface of many childhood solid tumors including neuroblastoma and a variety of sarcomas.
High-Risk Leukemia Clinical Trials Fund
$120,000 – will both pay for average cost of genetic sequencing and fill the gap between federal funding and actual cost of clinical trial participation for up to 10 HRL patients.
This fund is the top priority for Dr. Todd Cooper, director of the Pediatric Leukemia/Lymphoma Program, Evans Family Endowed Chair in Pediatric Cancer, and co-director of the integrated High-Risk Leukemia Program at Seattle Children’s. The first-of-its-kindHigh Risk-Leukemia Program greatly improves the experience of patient families, who meet with all the experts involved in their child’s care at one time. Those in-take meetings bring together care-providers from multiple institutions including transplant teams and lab researchers who provide genetic sequencing information to ensure the best match between each child and the most promising clinical trial for his or her leukemia. This fund supports the cost of those clinical trials, as well as the necessary genetic testing, thus helping improve outcomes for kids. Genetic testing costs on average $5,000 per patient and is rarely covered by insurance. The gap between federal funding and the actual cost of participation for each child enrolled in a clinical trial varies but is typically at least $7,000 for high-risk leukemia (HRL) trials – note this is higher cost than the general average for all cancer trials. In 2019, our High-Risk Leukemia team anticipates treating 30 patients in Seattle and providing remote consultations for up to 40 additional patients.
In honor of Cecile, Ian, Hanna, and Jack.
Children’s Circle of Care $10,000 Donation! Seattle Children’s Cancer Clinical Trials Fund
This fund is the top priority for Dr. Doug Hawkins who leads our Cancer and Blood Disorders unit. This fund helps cover the cost of studies for all types of cancer — so every child can benefit from the best therapies available. These trials impact hundreds of kids annually. In 2016, our oncology team ran 101 cancer research studies, with 899 enrollments (some patients enrolled in more than one study). Thanks to these clinical trials, and the donors who support them, survival rates as Seattle Children’s surpass the national average for nearly every type of cancer. Many of the promising cancer studies highlighted in our publications are supported by this fund. One recent example is a sarcoma study led by Dr. Hawkins and one of our new cancer team members Dr. Katie Albert. This blog post details the experience of one 5-year-old patient in the study whose tumor has disappeared entirely. The fund also supports a lot of other groundbreaking research, including Dr. Sarah Leary’s exciting Tumor Paint trial.
In 2020, Valley Girls and Guys launched a YES! Campaign as a way to do MORE to support the Cancer Clinical Trials fund during the unprecidented times that surrounded us. In January 2021, the board was excited to present Dr. Hawkins and Seattle Children’s Hospital with a $54,000 check. This money means that MORE trials can take place and more children can be helped in our fight to end ALL cancers.